Unknown

Dataset Information

0

Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance.


ABSTRACT: Metastable phenotypic state transitions in cancer cells can lead to the development of transient adaptive resistance or tolerance to chemotherapy. Here, we report that the acquisition of a phenotype marked by increased abundance of CD44 (CD44Hi) by breast cancer cells as a tolerance response to routinely used cytotoxic drugs, such as taxanes, activated a metabolic switch that conferred tolerance against unrelated standard-of-care chemotherapeutic agents, such as anthracyclines. We characterized the sequence of molecular events that connected the induced CD44Hi phenotype to increased activity of both the glycolytic and oxidative pathways and glucose flux through the pentose phosphate pathway (PPP). When given in a specific order, a combination of taxanes, anthracyclines, and inhibitors of glucose-6-phosphate dehydrogenase (G6PD), an enzyme involved in glucose metabolism, improved survival in mouse models of breast cancer. The same sequence of the three-drug combination reduced the viability of patient breast tumor samples in an explant system. Our findings highlight a convergence between phenotypic and metabolic state transitions that confers a survival advantage to cancer cells against clinically used drug combinations. Pharmacologically targeting this convergence could overcome cross-drug tolerance and could emerge as a new paradigm in the treatment of cancer.

SUBMITTER: Goldman A 

PROVIDER: S-EPMC7261372 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications


Metastable phenotypic state transitions in cancer cells can lead to the development of transient adaptive resistance or tolerance to chemotherapy. Here, we report that the acquisition of a phenotype marked by increased abundance of CD44 (CD44<sup>Hi</sup>) by breast cancer cells as a tolerance response to routinely used cytotoxic drugs, such as taxanes, activated a metabolic switch that conferred tolerance against unrelated standard-of-care chemotherapeutic agents, such as anthracyclines. We cha  ...[more]

Similar Datasets

| S-EPMC5291795 | biostudies-literature
2017-01-25 | GSE74557 | GEO
| S-EPMC5938463 | biostudies-literature
| S-EPMC8037590 | biostudies-literature
| S-EPMC6972814 | biostudies-literature
2024-02-20 | GSE255616 | GEO
| S-EPMC4298428 | biostudies-literature
| S-EPMC3024936 | biostudies-literature
2024-02-20 | GSE255615 | GEO
2024-02-20 | GSE255598 | GEO